EGFR and colorectal carcinoma: Our study implies clinical applications, based on the involvement of miR-425-5p targeted genes in EGFR tyrosine kinase inhibitor resistance pathway, suggesting that miR-425-5p overexpression might represents in CRC an epigenetic mechanism of resistance to anti-EGFR therapies.